Solanezumab
- Generic Name
- Solanezumab
- Brand Names
- -
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- 955085-14-0
- Unique Ingredient Identifier
- 5D6PWO0333
- Background
Solanezumab is under investigation for the treatment of Dementia, Alzheimers Disease, and Alzheimers Disease, Familial.
- Associated Conditions
- -
- Associated Therapies
- -
Solanezumab Safety Study in Japanese Patients With Alzheimer's Disease
- First Posted Date
- 2008-09-09
- Last Posted Date
- 2010-06-02
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 33
- Registration Number
- NCT00749216
- Locations
- 🇯🇵
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Tokushima, Japan
Effects of LY2062430 in Subjects With Mild-to-Moderate Alzheimer's Disease and in Healthy Volunteers
- First Posted Date
- 2006-05-24
- Last Posted Date
- 2009-10-07
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 25
- Registration Number
- NCT00329082
- Locations
- 🇺🇸
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Philadelphia, Pennsylvania, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.